ClinicalTrials.gg
RecruitingNCT06028659ENDOPHENOLUpdated Apr 8, 2025

Investigation of in Vivo Endogenous and/or Exogenous Production of Phenolic Metabolites Using (un)Targeted Metabolomics

An interventional study of Coffee and Water in Individual Variability in (Poly)Phenol Metabolism, sponsored by University of Parma. Recruiting at 1 site in Italy. Open to participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-08.

Sponsored by University of Parma · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
All
01

Study summary

Plant (poly)phenols is what we call a large number of substances that are produced by plants as secondary plant metabolites, which means substances that are not used for their growth and development but are necessary for them to survive. (Poly)phenols are divided in two major groups, flavonoids, and non-flavonoids, and each group contains a varied set of subgroups and substances. They are widely spread in fruit and vegetables that are part of the human diet, and, in general, studies have attributed many biological effects to the ingestion of (poly)phenols, especially in the prevention of non-communicable diseases. For this reason, research aims to understand their role in the health benefits of a diet that is rich in fruits and vegetables. When ingested, (poly)phenols are digested by both the human organism and the gut microbiota and are broken down into several smaller substances (catabolites) that are called low-molecular weight (poly)phenols (LMWP). Most of the absorbed (poly)phenols that reach our bloodstream and organs are LMWP.

For the proposed study, 30 healthy adults will be recruited and, if considered able to participate, will follow a standardized diet that is restricted in (poly)phenol intake and will be randomly divided into two groups: one will receive a known source of (poly)phenols (coffee) and the other will receive water, keeping the restriction of (poly)phenol from the diet. The duration of one phase is 4 days + 12 hours, during which urine, feces, and saliva will be collected. Then, after a 2-week-interval, subjects will repeat the experiment, except that this time the group who had coffee will have water, and vice versa. Again, urine and feces will be collected. The objective of the study is to identify and quantify LMWP mainly in urine, but also in feces, and try to understand how much was produced when there was no (poly)phenols in the diet compared with when there was ingestion of coffee (poly)phenols. The production of LMWP without coffee could be because of their production from other sources, like the metabolism of amino acids, proteins, and catecholamines (i.e. dopamine). The composition of the gut microbiota and relevant genetic information can alter the metabolism of (poly)phenols and will be considered in the analyses. Knowing how much of LMWP actually comes from the diet is important to understand the relevance and health benefits of these molecules.

Read the detailed description

The study will consist of a randomized cross-over trial and each arm will last 5 days. A total of thirty (30) healthy volunteers will be recruited for the study in Parma (PR), using announcements placed in the university, hospital, and public places. To allocate subjects to each arm, a list will be generated using a randomized block design by using Random Number Generator Pro (Segobit Software). This list will be blind for the PI and volunteers, as it will be made by a colleague not involved in the subjects' enrolment and using a numbered sequence in sealed, opaque envelopes.

Volunteers freely accepting to participate to the study will be asked for their written informed consent. Information to the volunteers will be provided before and separately from the consent form. These information sheets and the informed consent forms have been prepared according to the Oviedo Convention and consider the guide of the local Ethics Committee. After obtaining their written informed consent, volunteers will undergo a screening visit to determine eligibility and collect personal data.

Privacy of the volunteers will be assured through pseudoanonymization by the attribution of a personal alphanumeric code. Recruited volunteers will also sign an authorisation to the use of personal information and retrieved data.

After recruitment, subjects will attend a first visit, when personal data will be collected, and body composition and anthropometry parameters measured. Then, they will receive the foods, supplements, and materials necessary to follow the study. The recruited subjects will be requested to follow a low-(poly)phenol diet, which will be the same for all the volunteers and maintained for the whole period of the intervention study. The foods, preparation mode, and times for eating the meals will be provided by the sponsor. The diet will be personalised to approximate the necessary calories based on the measured basal metabolic rate, multiplied by the physical activity level set at 1.45, and there will be quantitative variations on the low-(poly)phenol diet based on the daily energy requirement: 1500 kcal/day, 1750 kcal/day, 2000 kcal/day, 2250 kcal/day, 2500 kcal/day, 2750 kcal/day, or 3000 kcal/day, all with nutritionally balanced amounts of protein, fat, and carbohydrates. In addition, participants will be requested to restrict physical exercise during the study duration.

Subjects will be asked to collect urine produced during the 60h prior the intervention, starting from the evening prior the first day of diet (from 21.00 of the night prior the first day of diet) and every 12 hours (60-48h, 48-36h, 36-24h, 24-12h, 12-0h), and to complete the food diary to check for compliance to the diet. Subjects are asked to bring collected urine to the the Human Nutrition Unit of the Food and Drug Department of the University of Parma.

On the morning of the third day of diet, subjects will be requested to arrive at Parma University in fasting conditions. Prior to receiving the intervention, fasting spot urine and saliva samples will be collected. Then, sugared-decaffeinated-coffee (3 doses of 50 mL each and 5g of sugar) or sugared-water (150 mL of water and 5g of sugar) will be provided according to randomization of the arms, along with a standardized breakfast consisting of a (poly)phenol-free, nutritionally balanced solid meal and water (ad libitum).

After breakfast, subjects will be asked to autonomously collect urine for the next 48h at specified timepoints (0 - 3h; 3 - 6h; 6 - 9h; 9 - 12h; 12 - 24h; 24 - 36h; and 36 - 48h), following the same personalized diet. Lastly, subjects will autonomously collect a fecal sample within 6 to 48h after the intervention.

On the morning of the last day, after the last urine collection, subjects will bring collected urine and fecal samples and the 5-day food diary to the Human Nutrition Unit of the Food and Drug Department of the University of Parma.

After the first arm, subjects will resume their habitual lifestyles for 2 consecutive weeks, subsequently, they will attend another visit, when all the anthropometric evaluations carried out during the first visit will be repeated and another kit with foods and information for the personalized diet will be given. With the study being a cross-over design, the protocol followed will be the same as the one described above (except for saliva sampling, which will only be performed once). Coming the third day of diet, subjects who ingested coffee in the prior arm of the study will ingest water, and vice-versa.

For this study, the sample size was estimated considering the mean concentration of coffee-derived (poly)phenols and their metabolites in urine as the primary outcome and the available literature on similar approaches and studies of the area. The number of 30 volunteers was established considering the accepted parameters for clinical trials (power set at 0.8 and α set at 0.05) possible dropouts (15% drop-out rate), and exclusion of volunteers to maintain the sample power for statistical analysis. Before any comparison is performed, the normality of each variable will be evaluated to choose the most appropriate statistical test. If metabolite data are normally distributed, data will be expressed as mean ± standard deviation and analysed using repeated measures t-test or ANOVA with post-hoc comparisons. If data are not normally distributed, they will be reported as median and Interquartile Range and the Friedman test with post hoc pairwise comparisons will be performed. P-value \< 0.05 will be regarded as statistically significant.

Unsupervised and supervised multivariate analysis will be used to identify and characterize the different urinary metabotypes, following the procedures developed by our research group for targeted metabolomics analysis of phenolic metabolites or when using untargeted metabolomics data. We will be using different clustering approaches to better explore the existing variability. This will serve to establish the number of clusters (i.e., phenolic metabotypes), the number of participants forming each cluster and the similarities among possible metabotypes.

The relationship between patterns of LMWP and their putative determinants (age, sex, ethnicity, lifestyle, anthropometrics, body composition, genotype, and gut microbiome) will be explored using correlation tests and multivariate analyses. P-value \< 0.05 will be regarded as statistically significant. Statistics will be carried out by the specialized staff of the Human Nutrition Unit, under the supervision of the PI, and in collaboration with the University teams in charge of microbial profiling and genotyping.

02

Conditions studied

  • Individual Variability in (Poly)Phenol Metabolism

Keywords

  • (poly)phenols
  • catabolites
  • coffee
  • metabolism
  • low-molecular-weight (poly)phenols
  • metabolomics
03

In context

Lead sponsor

University of Parma is the lead sponsor of 77 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Apparently healthy adults,
  • Age 20-40 years old,
  • (BMI) between 18-28,
  • Regular coffee consumers (at least 1 cup a day).

Exclusion criteria

Exclusion Criteria:

  • Clinical diagnosis of metabolic diseases,
  • Clinical diagnosis of cardiovascular diseases,
  • Clinical diagnosis of renal diseases,
  • Clinical diagnosis of digestive diseases,
  • Immunodeficiency
  • diseases (other than well-compensated hypothyroidism),
  • Mental disorders
  • Regular use of medication (except birth-control pills and hormone replacement therapies),
  • Use of antibiotics in the last month prior to enrollment,
  • Food allergies or intolerances,
  • Pregnancy
  • Lactation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Coffee

    In this arm, volunteers will receive, once, 3 decaffeinated coffees (150 mL total) with sugar as a known source of (poly)phenols.

    Other: Coffee

  • Other
    Control

    In this arm, volunteers will receive, once, 150 mL of sugared water as control.

    Other: Water

Interventions

  • OtherCoffee

    Decaffeinated coffee with 1 pack (5g) of sugar from commercially available brands prepared with commercially available domestic coffee machines.

  • OtherWater

    150 mL of hot water with 1 pack (5g) of sugar from commercially available brands prepared with commercially available domestic coffee machines.

06

What researchers measure

Primary outcomes

  1. Number and concentration of phenolic metabolites in urine

    Urine samples will be subjected to both targeted and untargeted liquid chromatography mass spectrometry analyses

    Time frame: Samples acquired from 60 hours prior to 48 hours after intervention or control

Secondary outcomes

  1. Identification and quantification of gut bacteria (genera and species) in feces

    Analysis of microbiota taxonomy at species level from bacterial DNA extracted from fecal samples.

    Time frame: Samples acquired from 6-48 hours after coffee or control

  2. Number and concentration of phenolic metabolites in feces

    Fecal samples will be subjected to both targeted and untargeted liquid chromatography mass spectrometry analyses

    Time frame: Samples acquired from 6-48 hours after coffee or control

  3. Identification and quantification of metabolites after in vitro fecal fermentation

    A set of (poly)phenol-rich substrates and protein-rich food items will be incubated and fermented in sealed jars to evaluate the ability of human microbiota to produce different phenolic metabolites.

    Time frame: Samples acquired from 6-48 hours after coffee or control

  4. Identification of single-nucleotide polymorphism analysis

    Genotyping for possibile genetic variations in genes related to (poly)phenol kinetics. Commercially available SNP arrays detect gene variability across the majority of the genome using a tagging SNP approach.

    Time frame: Single saliva samples collected from 1 hour to 30 minutes before the intervention with coffee or control.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The data shared will be those that underlie results in a publication.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be available from when published in peer-reviewed journals.

Access criteria: Data available in publications can be freely accessed. If further data is required to be shared, it will be assessed case by case.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2023 (actual). Primary completion is estimated for Jun 2025, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2023
First posted
Sep 8, 2023
StartActual
Oct 25, 2023
Primary completionEst.
Jun 30, 2025
CompletionEst.
Jun 30, 2025
Last update
Apr 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06028659
Lead sponsor
University of Parma
Responsible party
Pedro M. Mena Parreño (Principal Investigator, University of Parma) — Principal investigator
First posted
Sep 8, 2023
Start date
Oct 25, 2023
Primary completion
Jun 30, 2025 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
Apr 8, 2025

Study contacts

Pedro M Mena Parreño, PhD
Contact
pedromiguel.menaparreno@unipr.it
+393288087332
Letizia Bresciani, PhD
Contact
letizia.bresciani@unipr.it
Pedro M Mena Parreño, PhD
principal investigator · University of Parma

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion